Tirofiban for Brain Aneurysm

(iSPASM-2 Trial)

This trial explores a new treatment using tirofiban for individuals who have experienced a brain bleed from a ruptured aneurysm treated with endovascular coiling. The researchers aim to determine the safest dose and assess whether it helps prevent issues like delayed brain damage or blood vessel spasms. Participants will receive either tirofiban or a placebo through an IV for up to a week. Suitable candidates for this trial are those who recently had an aneurysm-induced brain bleed and underwent a specific coiling procedure. As a Phase 1/Phase 2 trial, this research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.

The trial does not specify if you need to stop all current medications, but you cannot participate if you need to continuously use aspirin, clopidogrel, ticagrelor, or tirofiban during the study.

Research has shown that tirofiban is generally safe for treating brain aneurysms. Studies indicate that using tirofiban during procedures like stent-assisted coiling of ruptured aneurysms is both feasible and safe. For instance, one study found it did not increase the risk of bleeding. Another study reported a low risk of serious issues like bleeding or clots with tirofiban. While some reports mention minor risks, tirofiban is well-tolerated and does not significantly raise the risk of bleeding. Overall, evidence suggests tirofiban is safe for short-term use in similar treatments.¹²³⁴⁵

Tirofiban is unique because it offers a new approach to treating brain aneurysms by targeting platelet aggregation, which is not the primary focus of traditional treatments. Most current options, like surgical clipping or coiling, physically address the aneurysm itself but do not modify the underlying blood clotting processes. By using tirofiban, an antiplatelet agent, researchers hope to reduce the risk of clot-related complications after endovascular coiling. This could potentially enhance recovery by preventing the formation of harmful blood clots, offering a novel layer of protection that standard mechanical methods do not provide.

Research has shown that tirofiban is safe and effective for treating brain aneurysms. Studies have found that it can lower the risk of blood clots without increasing bleeding problems. In this trial, participants will receive either a continuous IV infusion of tirofiban or a saline placebo for 1, 3, 5, or 7 days after endovascular coiling. Previous studies have demonstrated that patients using tirofiban experienced better recovery outcomes, meaning they were more likely to improve from their condition. Specifically, another study showed that tirofiban significantly reduced blood clot-related issues compared to other treatments. Overall, these findings suggest that tirofiban could be a promising option for enhancing recovery in patients with brain aneurysms.¹²⁶⁷⁸